Xeloda Alternatives Compared
| Xeloda | Yervoy | Avastin |
|
|---|
| Xeloda (capecitabine) | Yervoy (ipilimumab) | Avastin (bevacizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Colorectal Cancer, Breast Cancer - Metastatic, Breast Cancer. Xeloda may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Melanoma - Metastatic, Malignant Pleural Mesothelioma, Melanoma, Renal Cell Carcinoma, Colorectal Cancer. Yervoy may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Glioblastoma Multiforme, Colorectal Cancer, Fallopian Tube Cancer, Cervical Cancer, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Peritoneal Cancer, Renal Cell... View more |
Related suggestions Colorectal Cancer
|
|||||||||||||||||||||||
| More about Xeloda (capecitabine) | More about Yervoy (ipilimumab) | More about Avastin (bevacizumab) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
|||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Xeloda has an average rating of 6.7 out of 10 from a total of 30 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 30% reported a negative effect. |
Be the first to share your experience with this drug. |
Avastin has an average rating of 7.7 out of 10 from a total of 27 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 13% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
Common side effects include:
See also: Xeloda side effects in more detail. |
See also: Yervoy side effects in more detail. |
See also: Avastin side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Xeloda prices and generic prices |
View all Yervoy prices |
View all Avastin prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
Other bevacizumab brands include: Alymsys, Mvasi, Vegzelma, Zirabev | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
0.75 hours |
352.8 hours |
480 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 242 drugs are known to interact with Xeloda:
|
A total of 142 drugs are known to interact with Yervoy:
|
A total of 29 drugs are known to interact with Avastin:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
April 30, 1998 |
March 25, 2011 |
February 26, 2004 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.